Regeneron Pharmaceuticals, Inc. $REGN Stock Position Reduced by ASR Vermogensbeheer N.V.

ASR Vermogensbeheer N.V. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 9,352 shares of the biopharmaceutical company’s stock after selling 133 shares during the quarter. ASR Vermogensbeheer N.V.’s holdings in Regeneron Pharmaceuticals were worth $4,909,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Finally, Curat Global LLC bought a new position in Regeneron Pharmaceuticals in the first quarter worth about $32,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on REGN shares. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a report on Monday, August 4th. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price target on the stock. Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Price Performance

REGN opened at $600.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock’s fifty day moving average is $572.12 and its 200-day moving average is $567.94. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,024.36. The company has a market capitalization of $63.59 billion, a PE ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same period in the previous year, the business earned $11.56 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.